金刚烷胺治疗吉兰-巴雷综合征患者的疲劳:一项随机、双盲、安慰剂对照的交叉试验  

Amantadine for treatment of fatigue in Guillain-Barré syndrome: A randomised, double blind, placebo controlled, crossover trial

作　　者：Garssen M.P.J. Schmitz P.I.M. Merkies I.S.J. 王鹏 

机构地区：[1]Department of Neurology, Erasmus Medical Center Rotterdam, PO Box 1738, 3000 DR Rotterdam, Netherlands,Dr.

出　　处：《世界核心医学期刊文摘（神经病学分册）》2006年第5期47-47,共1页Digest of the World Core Medical Journals:Clinical Neurology

摘　　要：Objective: Fatigue is a major complaint in patients with immune mediated polyneuropathies. Despite apparently good physical recovery after Guillain-Barré syndrome (GBS), many patients remain restricted in daily and social activities, and have a decreased quality of life. In this trial, the effect of amantadine on severe fatigue related to GBS was studied. Methods: During the pre-treatment phase, all patients were monitored for 2 weeks. Only patients with severe fatigue, defined as a mean fatigue score of ≥ 5.0 on the Fatigue Severity Scale (FSS), were randomised for this double blind, placebo controlled, crossover study. Primary outcome measure was improvement of at least 1 point on the FSS. Secondary outcome measures were impact of fatigue, anxiety and depression, handicap, and quality of life. Results: In total, 80 patients with GBS were randomised, of whom 74 were included for analysis. Fatigue appeared to be reduced already during the pre-treatment phase (p = 0.05), probably due to increased attention provided to the patients. No significant differences in any of the primary and secondary outcome measures were found. Conclusions: Amantadine was not superior to placebo. Because fatigue remains a serious complaint, other studies evaluating new treatment options are strongly recommended.Objective： Fatigue is a major complaint in patients with immune mediated polyneuropathies. Despite apparently good physical recovery after GuiUain-Barre syndrome （GBS）, many patients remain restricted in daily and social activities, and have a decreased quality of life. In this trial, the effect of amantadine on severe fatigue related to GBS was studied. Methods： During the pre-treatment phase, all patients were monitored for 2 weeks. Only patients with severe fatigue, defined as a mean fatigue score of ≥5.0 on the Fatigue Severity Scale （FSS）, were randomised for this double blind, placebo controlled,crossover study. Primary outcome measure was improvement of at least 1 point on the FSS. Secondary outcome measures were impact of fatigue, anxiety and depression, handicap, and quality of life. Results： In total, 80 patients with GBS were randomised, of whom 74 were included for analysis. Fatigue appeared to be reduced already during the pre-treatment phase （p = 0. 05）,

关 键 词：吉兰-巴雷综合征 安慰剂对照 交叉试验 金刚烷胺 治疗前 患者 疲劳 随机 双盲 多发性神经病变 

分 类 号：R745.43[医药卫生—神经病学与精神病学] R-3[医药卫生—临床医学]